NASDAQ:HSDT - Nasdaq - US42328V8019 - Common Stock - Currency: USD
NASDAQ:HSDT (4/28/2025, 8:14:41 PM)
0.2993
+0.01 (+2.5%)
The current stock price of HSDT is 0.2993 USD. In the past month the price decreased by -28.74%. In the past year, price decreased by -89.57%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 27.1 | 224.65B | ||
ISRG | INTUITIVE SURGICAL INC | 67.28 | 184.15B | ||
BSX | BOSTON SCIENTIFIC CORP | 37.84 | 151.13B | ||
SYK | STRYKER CORP | 30.06 | 139.89B | ||
MDT | MEDTRONIC PLC | 15.74 | 107.78B | ||
BDX | BECTON DICKINSON AND CO | 14.71 | 58.76B | ||
EW | EDWARDS LIFESCIENCES CORP | 29.05 | 44.41B | ||
IDXX | IDEXX LABORATORIES INC | 38.58 | 35.17B | ||
RMD | RESMED INC | 25.79 | 34.39B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 15.16 | 31.17B | ||
DXCM | DEXCOM INC | 43.14 | 27.91B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 16.09 | 23.74B |
Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The company is headquartered in Newtown, Pennsylvania and currently employs 21 full-time employees. The company went IPO on 2014-06-27. The firm is engaged in the medical device field focused on neurologic deficits using an orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS), is a non-implantable medical device, inclusive of a controller and mouthpiece, which delivers mild electrical stimulation to the surface of the tongue to provide treatment of gait deficit and chronic balance deficit. PoNS Therapy utilizes the PoNS device in conjunction with supervised therapeutic exercise. The PoNS Therapy consists of condition-specific exercises for movement control, including balance and gait training and breathing and awareness training, which are tailored to focus on the individual patient’s functional deficits.
HELIUS MEDICAL TECHNOLOGIES
642 Newtown Yardley Road
Newtown PENNSYLVANIA 18940 US
CEO: Dane C. Andreeff
Employees: 22
Company Website: https://heliusmedical.com/
Investor Relations: https://heliusmedical.com/index.php/investor-relations/overview
Phone: 12159446100
The current stock price of HSDT is 0.2993 USD. The price increased by 2.5% in the last trading session.
The exchange symbol of HELIUS MEDICAL TECHNOLOGIES is HSDT and it is listed on the Nasdaq exchange.
HSDT stock is listed on the Nasdaq exchange.
6 analysts have analysed HSDT and the average price target is 4.08 USD. This implies a price increase of 1263.18% is expected in the next year compared to the current price of 0.2993. Check the HELIUS MEDICAL TECHNOLOGIES stock analysts ratings, price target forecast and up-and down grades for more detailed information.
HELIUS MEDICAL TECHNOLOGIES (HSDT) has a market capitalization of 1.83M USD. This makes HSDT a Nano Cap stock.
HELIUS MEDICAL TECHNOLOGIES (HSDT) currently has 22 employees.
HELIUS MEDICAL TECHNOLOGIES (HSDT) has a resistance level at 0.3. Check the full technical report for a detailed analysis of HSDT support and resistance levels.
The Revenue of HELIUS MEDICAL TECHNOLOGIES (HSDT) is expected to grow by 8.97% in the next year. Check the estimates tab for more information on the HSDT EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
HSDT does not pay a dividend.
HELIUS MEDICAL TECHNOLOGIES (HSDT) will report earnings on 2025-05-12, after the market close.
HELIUS MEDICAL TECHNOLOGIES (HSDT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.73).
The outstanding short interest for HELIUS MEDICAL TECHNOLOGIES (HSDT) is 0.27% of its float. Check the ownership tab for more information on the HSDT short interest.
ChartMill assigns a fundamental rating of 2 / 10 to HSDT. While HSDT seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months HSDT reported a non-GAAP Earnings per Share(EPS) of -5.73. The EPS increased by 60.37% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -331.51% | ||
ROE | -1108.78% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 43% to HSDT. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 88.61% and a revenue growth 8.97% for HSDT